CARE Ratings Ltd Upgraded to Buy on Strong Technical and Financial Performance

Technical Upgrade Spurs Rating Change

The primary catalyst for the upgrade on 4 August 2026 was a significant improvement in CARE Ratings’ technical grade, which shifted from mildly bullish to bullish. Key technical indicators underpinning this change include a bullish Moving Average Convergence Divergence (MACD) on the weekly chart, bullish Bollinger Bands on both weekly and monthly timeframes, and a bullish daily moving average trend. Additionally, the On-Balance Volume (OBV) indicator is bullish on weekly and monthly scales, signalling strong buying interest.

While some indicators such as the Know Sure Thing (KST) and Dow Theory remain mildly bearish or mildly bullish on monthly and weekly charts, the overall technical momentum has strengthened sufficiently to warrant a positive outlook. The stock’s price action supports this, with the current price at ₹1,726.55, up 0.74% on the day, trading close to its 52-week high of ₹1,836.00. The recent weekly return of 3.20% outpaces the Sensex’s 2.17%, and the one-month return of 4.78% significantly exceeds the Sensex’s 0.86%, reinforcing the bullish technical stance.

Financial Trend: Consistent Growth and Profitability

CARE Ratings has demonstrated a strong financial trajectory, with positive results reported for 11 consecutive quarters, including the latest Q4 FY25-26. The company remains net-debt free, a critical factor enhancing its financial stability and flexibility. Return on Capital Employed (ROCE) for the half-year period stands at an impressive 24.81%, underscoring efficient capital utilisation.

Profit after tax (PAT) for the first nine months has risen to ₹145.40 crores, while profit before tax excluding other income (PBT less OI) for the quarter grew by 28.77% to ₹56.30 crores. These figures highlight sustained operational strength and margin expansion. Institutional investors hold a significant 54.99% stake, reflecting confidence from sophisticated market participants who typically conduct rigorous fundamental analysis.

Quality Assessment: Strong Fundamentals Amid Moderate Growth

The quality of CARE Ratings’ business remains robust, supported by its net-debt free balance sheet and consistent profitability. However, the company’s long-term growth rates warrant cautious optimism. Net sales have grown at a compound annual growth rate (CAGR) of 13.75% over the past five years, while operating profit has expanded at 15.76% annually. Although these figures indicate steady progress, they are moderate relative to some high-growth peers in the capital markets sector.

Return on Equity (ROE) stands at 18.4%, reflecting efficient utilisation of shareholder capital. Despite this, the valuation appears stretched, with a price-to-book (P/B) ratio of 5.5, categorising the stock as very expensive compared to its historical averages and peer group. The price-to-earnings-to-growth (PEG) ratio of 1.3 suggests that the market is pricing in continued profit growth, which has risen by 24.7% over the past year, outpacing the stock’s 4.79% return in the same period.

Valuation: Premium Pricing Reflects Market Confidence

CARE Ratings’ current market capitalisation classifies it as a small-cap stock, with a market cap grade reflecting this status. The premium valuation metrics indicate strong investor confidence, likely driven by the company’s consistent earnings growth and net-debt free position. However, the elevated P/B ratio signals that investors are paying a significant premium for quality and stability, which may limit upside potential if growth slows.

Comparatively, the stock has outperformed the Sensex over multiple time horizons, delivering a 138.19% return over three years and 143.28% over five years, versus the Sensex’s 19.34% and 44.25% respectively. This outperformance underscores the stock’s ability to generate shareholder value over the long term despite its premium valuation.

Risks and Considerations

Despite the upgrade, investors should remain mindful of certain risks. The company’s moderate sales growth rate of 13.75% annually may not satisfy those seeking rapid expansion. Furthermore, the premium valuation metrics imply that any slowdown in earnings growth or adverse market conditions could lead to valuation compression.

Technical indicators, while currently bullish, also present mixed signals on monthly charts, with some mildly bearish trends persisting. This suggests that investors should monitor price action closely for any signs of reversal or consolidation.

Conclusion: A Balanced Buy Recommendation

CARE Ratings Ltd’s upgrade to a Buy rating by MarketsMOJO reflects a comprehensive improvement across four key parameters: technicals, financial trends, quality, and valuation. The company’s strong quarterly performance, net-debt free status, and bullish technical indicators provide a solid foundation for future growth. However, the premium valuation and moderate sales growth rate counsel a measured approach.

For investors seeking exposure to a fundamentally sound small-cap in the capital markets sector with consistent profitability and improving technical momentum, CARE Ratings presents an attractive proposition. The stock’s historical outperformance relative to the Sensex further supports its appeal as a long-term investment.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today